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Ancora Pharmaceuticals: Overview
•Demonstrated track record in producing commercially 
relevant synthetic carbohydrates across the 
glycobiology spectrum
•Founded on the groundbreaking carbohydrate synthesis 
technology from Prof. Dr. Peter Seeberger (Max Planck)
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•Primary R&D focus: glycoconjugate vaccines for 
prevention of nosocomial and opportunistic infections
•World class team of managers and advisors
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•Business focus: build value through partnered and 
proprietary programs
Management and Advisors
• Richard Hoffman, J.D., M.B.A. CEO;  20+ years in biopharmaceutical corporate and 
business development (Abgenix, Ablexis)
• Stewart Campbell, Ph.D.  Vice President - Research & Development; 18 years in 
biopharmaceutical therapeutic development; 16 years carbohydrate chemistry expertise.
• Obadiah Plante, Ph.D.  Co-founder, Senior Director - Vaccine Discovery; 15 years 
carbohydrate chemistry expertise.
• Professor Peter Seeberger, Ph.D. Director, Scientific Founder; World leader in 
carbohydrate chemistry and glycobiology; Elected Director of the Max Planck Institute
3
• Barry Buckland, Ph.D. Director and Scientific Advisor; ex-VP Bioprocess for Merck 
Vaccines; 30+ years vaccine & biologic product development
• Florian Schodel, M.D.  Scientific Advisor; ex-VP Clinical Development for Merck 
Vaccines; 20+ years vaccine research and clinical development
• George M. Siber, M.D. Scientific Advisor; ex-CSO for Wyeth Vaccines; 30+ years 
vaccine research & development
• Bruce Forrest, M.D., M.B.A. Corporate and Scientific Advisor; ex-SVP Vaccine 
Research & Development for Wyeth Vaccines (Pfizer); 20+ years vaccine research and 
clinical development
• Rahul Singhvi, Sc.D., MBA. Director; former President/CEO of Novavax; former 
scientist at Merck Vaccines.
©2012 Ancora Pharmaceuticals Inc.
• Commercially Validated Approach: 
– Why only 3 pathogens addressed so far?
Glycoconjugate Vaccines –
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• Major Barrier: 
– Limited access to defined carbohydrate material
Carbohydrate Production:
State-of-the-Art BioProcessing Can Be Limiting
Biological
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Chemical Synthesis Platform Unlocks 
Carbohydrate Space
Building block Assembly Processing 
Ancora synthesis technology platform produces defined structures
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technology capabilities methodologies
No limitation to structure or material access –
Ancora has completed every target structure to date
Opens entire glycobiology application space











































































Demonstrated Production of Diverse, Complex 
Mammalian Carbohydrate Structures
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Ancora Platform Provides Access to











Design and optimize for desired biological profile
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Synthetic Antigens Provide 
Excellent Conjugation Control
Purified




Bromuro et al. Vaccine  28 (2010) 2615
(Novartis Vaccines)
Kabanova et al. Vaccine  29 (2010) 104
(Novartis Vaccines)
Retention time
Ancora Platform Capabilities: Scalable to Support 
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Cost Competitive
Ancora Vaccine Portfolio:
Focus on Nosocomial Infections
Program
Chemistry Biological Function Preclinical Development Clinical Development
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Staphylococcus Vaccine Program:
Antigen Optimization via “Med Chem”
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• Target Populations and Medical Need:
• Incidence: 
• > 1.7 MM nosocomial infections annually
• CoNS and S. aureus in top five
• At-risk populations:
• Elective Cardiovascular Surgery – 7 MM procedures
• Orthopedic Surgery – > 1 MM procedures
• End-Stage Renal Disease – 600,000 patients
Staphylococcus Vaccine Opportunity
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• High drug resistance (MRSA), high mortality rate (20% of HAI)
• High economic burden:  >$30,000/ICU patient
• Staphylococcus as a Target:
• Gram positive, biofilm producing bacterium
• Usually encapsulated (Types 5, 8, 336 account for most human infections)
• Complex infection life-cycle  multi-valent approach likely required
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Staphylococcal PIA/PNAG: 
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Int. J. Antimicrob. Ag. (2008) 32S:S71
J. Infect. Dis. (2005) 192:2012
• dPNAG provide physical interface between bacterium and biofilm
• Human anti-dPNAG antibody levels correlated with in vitro OPA activity
Precedent for PNAG as a Target Antigen:














Pier group Science 284 (1999) 1523
Pier group Infect Immun 73 (2005) 6752
Antigen size, functional group pattern, conjugation UNCONTROLLED
Sites
Immunogenic; active in vitro and in vivo
Deacetylation required for immunoprotection  optimum pattern UNCLEAR
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R = H, Ac
Requires directed empirical and rational approach
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Synthetic PNAG/dPNAG fragments 
covering two extremes:  
fully N-acetylated, fully N-deacetylated









R = Uniformly H or Ac
n = 5 or 9
TT
19
Showed synthetic dPNAG conjugate 
provides passive immunoprotection
Pier, Nifantiev groups Infect Immun 78 (2010) 764
Acetylation patterns, pattern repeats 
not addressed
Protection after active immunization not 
demonstrated
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dPNAG Chemical Space:






• Grants access to the ENTIRE dPNAG chemical space


































Ancora Staphylococcus Vaccine Program: 



















“Medicinal Chemistry” approach to identifying best Ag
R = Patterned H, Ac
Antigen size, functional group pattern, conjugation are EXACT
Rational antigen library design  head-to-head testing
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Staphylococcus Vaccine Program:
Functional Proof-of-Concept
In vitro opsonophagocytosis assay (OPA):











































































































In vitro: Antisera selectively bind bacteria (WBE)










Murine Lethal Challenge Model
• S. aureus Newman inoculum: 
5.6 x 108 (LD50)
• CD1 outbred mice 
(n = 10 per group)
• Schedule: 3 x 10 ug @ 11-day 

















• Trend: dPNAG-KLH conjugates showed better protection vs. controls
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Staphylococcus Vaccine Program:
Competing Antibodies Phenomenon
• Lee, Pier and coworkers characterized 
neutralizing effect of combined anti-CP and anti-
dPNAG Abs both in vitro (OPA) and in vivo
(bacteremia, skin abscess models)
• Identified the same phenomenon in sera from 
bacteremia patients
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Skurnik et al. J. Clin. Invest.  120 (2010) 3220
• Traced mechanism to direct binding of 
















































Type 5 (- charge every 3rd unit)
Staphylococcus Vaccine Program:
Potential Solution to Competing Antibodies
New dPNAG Antigen Design Criteria
• ≤ 50% N-acetylation degree
• de-N-acetylated residues spaced by two 
intervening residues were disallowed
• ≤ 2 de-N-acetylated residues allowed in positions 
complementary to the CP ManAcA residues in an 
entire sequence (length dependent)
• ≤ 3 consecutive N-acetylated residues allowed
0 0 0 1 1 1 0 0 0 1
0 0 0 1 1 1 0 0 1 1
0 0 0 1 1 1 0 1 0 1
0 0 1 1 1 0 0 0 1 1
0 0 1 1 1 0 1 0 1 0
0 1 0 1 0 1 0 1 0 1
1 0 0 0 1 1 1 0 0 0
1 0 0 0 1 1 1 0 0 1
1 0 0 1 1 1 0 0 0 0
1 0 1 0 1 0 1 0 0 1
1 = NHAc 
0 = NH2
Permutations for dp = 10
Binary 
algorithm
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Desired output: Improved antigen devoid of anti-CP interference properties
Moraxella Vaccine Program:
Targeting Novel “Core Structures”
26©2012 Ancora Pharmaceuticals Inc.
Moraxella catarrhalis Vaccine Program
Target Antigen Overview: β-chain
Significant unmet medical need
• COPD: Over 2 million infections annually (2nd)
• Otitis media: Over 30% of acute otitis media cases (3rd)
• A leading cause of LRTIs in vulnerable populations  
• Widespread drug resistance
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• Gram negative lipo-oligosaccharide (LOS) class
• Critical for survival and virulence
• A, B, and C serotypes:  95% of human infections












Peng et al. FEBS J 274 (2007) 5350
Goal:   Identify antigen structures and substructures cross-
protective across all major MXLA strains
LOS core oligosaccharide
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Moraxella Vaccine Program:
Antigen Design





















































































Antigen library synthesized 
and conjugated
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Moraxella Vaccine Program: 
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Moraxella Vaccine Program:























SBA titers ≤ 1:250 for parent and cross-reactive Ag’s (n = 4 mean shown)
0
20
KLH Neg Ctrl Analog 3 Analog 4 ST A Analog 5
ELISA cross-reactivity translates into SBA activity
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Pseudomonas Vaccine Program:
Targeting Biofilm & “Hybrid Core” Structures
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Pseudomonas Vaccine Program
Significant Market Opportunity:
•2nd leading cause of ventilator associated pneumonia
•3rd leading cause of hospital-acquired pneumonia
•CF Patients: Most common lung infection, leading cause of 
morbidity and mortality




• 3 potential targets based on conserved nature, 
virulence role and colonization
• Alginate biofilm (1) expressed in chronic 
mucoid infections
• O-antigens (2) expressed in acute non-mucoid
infections
• LOS core (3) expressed in all infection stages






Trends Mol. Med.  (2008) 14:120
Pseucomonas Vaccine Program:
Automated Synthesis of Alginate Antigen
Design and Chemistry Approach
• Series of β-mannuronic acids of varying length
• Assembled in a day from a one building block 
(1) using Ancora’s automated synthesizer 
• Functional group for subsequent conjugation
• Evaluation in progress 
• Collaboration with Leiden University
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Walvoort et al. Angew. Chem. Int. Ed. 51 (2012) 4393
Ancora‘s automated carbohydrate synthesizer
Ancora Summary
• Diverse, broadly applicable carbohydrate synthesis platform
• Demonstrated track record of generating relevant synthetic 
carbohydrate antigens (defined, homogeneous)
• Internal focus on glycoconjugate vaccines for the prevention of 
nosocomial and other infections
• Excellent team of experienced managers and advisors
• Business strategy: partner after demonstration of preclinical POC
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